J. Rosing et al., CHARACTERIZATION OF 2 FORMS OF HUMAN FACTOR-VA WITH DIFFERENT COFACTOR ACTIVITIES, The Journal of biological chemistry, 268(28), 1993, pp. 21130-21136
Factor Va is an essential cofactor in factor Xa-catalyzed prothrombin
activation. Purified human factor Va appears to consist of a heavy cha
in (M(r) almost-equal-to 105,000) and a light chain doublet with M(r)
almost-equal-to 74,000 and almost-equal-to 71,000. We separated factor
Va by chromatography on a Mono-S column into two fractions, designate
d factors Va1 and Va2. Factor Va1 contains the light chain with M(r) a
lmost-equal-to 74,000, and factor Va2 exclusively contains the light c
hain with M(r) almost-equal-to 71,000. The two forms of factor Va expr
ess different cofactor activities when prothrombin is activated at low
phospholipid concentrations or on membranes containing low amounts of
phosphatidylserine in phosphatidylcholine. Compared with factor Va2,
much higher amounts of factor Va1 are required for factor Xa.Va comple
x formation at the membrane surface. Once incorporated into the prothr
ombinase complex, factors Va1 and Va2 are equally active in prothrombi
n activation. This indicates that the two forms of factor Va do not di
ffer in their ability to promote the catalytic activity of factor Xa o
r to interact with prothrombin. Direct binding experiments show that t
he different cofactor activities are explained by a greatly impaired a
bility of factor Va1 to bind to negatively charged membranes. Factor V
is also separated into two protein peaks after chromatography on a Mo
no-S column. Upon incubation with thrombin, the first peak yields fact
or Va1 and the second peak factor Va2. The same two forms of factor Va
were generated when freshly prepared plasma samples or platelet suspe
nsions were treated with thrombin. This shows that the heterogeneity o
f the light chain domain is an intrinsic property of both plasma and p
latelet factor V. It is hypothesized that the heterogeneity is caused
by small differences in the carboxyl-terminal C2 domain of factor V th
at are introduced as the result of post-ribosomal processing.